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Abstract: Although metastasis is the primary cause of death in patients with malignant solid tumors,
efficient anti-metastatic therapies are not clinically available currently. Sulfated glycosaminoglycans
from marine sources have shown promising pharmacological effects, acting on different steps of
the metastatic process. Oversulfated dermatan sulfates from ascidians are effective in preventing
metastasis by inhibition of P-selectin, a platelet surface protein involved in the platelet-tumor
cell emboli formation. We report in this work that the heparan sulfate isolated from the
viscera of the ascidian Phallusia nigra drastically attenuates metastases of colon carcinoma cells
in mice. Our in vitro and in vivo assessments demonstrate that the P. nigra glycan has very low
anticoagulant and antithrombotic activities and a reduced hypotension potential, although it efficiently
prevented metastasis. Therefore, it may be a promising candidate for the development of a novel
anti-metastatic drug.
Keywords: marine invertebrates; glycosaminoglycans; platelets; circulating tumor cells; circulating
tumor microemboli; hematogenous metastasis
1. Introduction
Metastasis is a multi-step process by which cells from a primary tumor invade the adjacent
extracellular matrix, reach the blood or lymphatic vessels, travel through circulation and extravasate
the vessel wall to invade a distant tissue and form secondary tumors [1]. During the hematogenous
dissemination, tumor cells release cytokines in the bloodstream that activate platelets and the
coagulation system [2]. Many glycoproteins at the surface of circulating tumor cells (CTCs) exhibit a
specific epitope described as sialyl-Lewis X (or sialyl-Lewis A). These epitopes are recognized and
bind to P-selectin expressed on the membrane of activated platelets, which lead to the formation of a
platelet cloak around CTCs. Additionally, platelet and tumor cell interaction is reinforced by fibrin
accumulation around these cloaks, originating a circulating tumor microemboli (CTM) [3].
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CTM protects tumor cells from circulatory mechanical forces and immune cell attack (e.g., natural
killer cells) in the bloodstream [4,5]. Both physical stress and immune surveillance make the bloodstream
a hostile environment for CTCs. It is estimated that only 0.01% of tumor cells released in the circulation
successfully form metastases [6]. Other than mechanically protecting tumor cells, platelets have the
intrinsic ability to interact with endothelium, which facilitates the arrest of CTCs in capillaries at
metastatic sites, leading to extravasation [7]. In this context, preventing P-selectin binding and the
formation of CTMs might decrease the chances of CTC survival in the bloodstream, thus, hindering
metastasis formation [8,9].
Heparan sulfate (HS) is a glycosaminoglycan (GAG) expressed in virtually all cells throughout
the body. It is mostly found at the cell surface and at the extracellular matrix, forming heparan sulfate
proteoglycans (HSPGs) such as Syndecan, Glypican, Perlecan, etc. [10]. Specific interactions of HS
with its ligands such as growth factors and receptors, regulate coagulation, inflammation, metastasis,
viral infection and many other biological processes [11,12]. Both HS and its analog heparin (HEP)
are composed of repetitive disaccharide unities containing α-glucosamine and uronic acid residues
linked by (1→4)-glycoside bonds. HS is enriched in N-acetyl α-glucosamine→β-glucuronic acid
disaccharides bearing different sulfation patterns, whereas HEP is composed mainly of N,6-disulfated
α-glucosamine→2-sulfated α-iduronic acid disaccharides [13].
GAG-based drugs currently approved for medical use, such as unfractionated (UFH) and
low-molecular-weight (LMWH) heparin, chondroitin sulfate (CS) and hyaluronic acid are obtained
from tissues of vertebrate animals. Nevertheless, GAG-like polysaccharides found in different marine
invertebrates such as clams (mollusks), sea cucumbers (echinoderms) and ascidians (Subphylum:
Urochordata; Class: Ascideacea) have shown promising therapeutic effects in different animal models of
human diseases [14–16]. In the ascidian Styela plicata, for instance, HEP-like glycans were found in
intracellular granules of oocyte test cells and hemolymph basophil-like cells [17]. This glycan is enriched
in disaccharides containing 2-sulfated α-iduronic acid linked to N,6-disulfated α-glucosamine (~75%)
or N-sulfated α-glucosamine (~25%) and was shown to attenuate inflammation in animal models
of colitis. Moreover, this polysaccharide also yielded a nano-derivative able to inhibit proliferation
and invasiveness of breast cancer cells [18,19]. Interestingly, the ascidian HEP has significantly lower
anticoagulant activity than pharmaceutical UFH from porcine mucosa [20,21].
Recently, we isolated an HS-like glycan (PNH) from the viscera of the ascidian Phallusia nigra.
Structural analyses by solution 1H and 13C nuclear magnetic resonance (NMR) (Figure 1A) showed
that PNH is a highly heterogeneous HS enriched in 2-sulfate β-glucuronic and 6-sulfate N-acetyl
α-glucosamine units (Figure 1B) [21]. The aPTT assay revealed that PNH has an anticoagulant activity
approximately 60-fold lower than UFH (Figure 1C); nevertheless, PNH was still able to inhibit the
binding of tumor cells to P-selectin at doses 11-fold lower than UFH, as depicted in Figure 1D [21].
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Figure 1. Chemical composition, anticoagulant activity and P-selectin binding blockage by the
heparan sulfate from Phallusia nigra (PNH). (A) 1H NMR spectrum of PNH. For details on the signals
annotated in the spectra, check reference [21]. (B) Proportions of PNH major disaccharides components.
(C) Anticoagulant activities (expressed as heparin International Units (IU/mg) of PNH (blue circles) and
heparin (gray triangles) determined by aPTT clotting assays. (D) Doses (EC50) of PNH and heparin
necessary to inhibit adhesion of LS180 colon carcinoma cells to P-selectin immobilized onto microplate
wells. This experiment was repeated and is similar to the one shown in reference [21]. * (p < 0.05).
Modified (A,C) or similar (D) to reference [21].
In this study, using mouse models we demonstrate that PNH can prevent lung metastasis of
colon carcinoma cells by inhibiting the formation of CTMs. Additionally, we showed that PNH does
not activate the coagulation zymogen factor XII (FXII), suggesting its low hypotension potential.
Although pharmaceutical UFH and LMWHs have also shown satisfactory P-selectin mediated
anti-metastatic activities, they might provoke bleeding in patients [22,23]. Therefore, a compound
with ultra-low anticoagulant activity and high efficacy in preventing metastasis, such as PNH, is a
promising candidate for therapeutic targeting of P-selectin.
2. Results
2.1. PNH Has no Cytotoxic Effect on Tumor Cells
Once we have confirmed the purity and physical-chemical features of the PNH molecule [21],
we began to evaluate the in vitro antitumor activity of this molecule. First, we assessed whether PNH
has cytotoxic effects on the MC-38 colon carcinoma cell line using an MTT assay. The viability of cells
incubated with media supplemented with crescent concentrations of PNH (0.1–10.0 µg/mL) showed
no statistically significant differences when compared with those incubated with media without the
glycan (control) (Figure 2). This result shows that PNH does not exert in vitro cytotoxic effects on
MC-38 cells.
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Figure 2. Cytotoxic effect of P. nigra heparan sulfate (PNH). 2 × 104 MC-38 cells were cultured in the
presence of different concentrations of PNH for 24 h. MTT was added during the last 2 h and the
absorbance was measured at 560 nm. The percentage of viable cells was calculated relative to control.
Three independent assays were performed and data were compared by analysis of variance (ANOVA);
NS = no significant statistical difference.
2.2. PNH Hinders the Formation of CTMs
The interaction of circulating tumor cells with platelets is responsible for the formation of CTMs
and is essential to the successful seeding at metastatic sites [3]. This interaction is primarily mediated by
P-selectin and our results showed that PNH strongly inhibits the binding of tumor cells to immobilized
P-selectin in vitro (Figure 1D). Hence, the ability of PNH to prevent the formation of CTMs was
assessed by quantifying the aggregation of GFP-positive MC-38 cells (MC-38GFP) to activated platelets
in the lung microvasculature (Figure 3A–C). C57BL/6 mice were intravenously injected (i.v. injection)
with PNH (1 mg/Kg) or UFH (20 mg/kg) 10 min before i.v. injection of MC-38GFP cells. After 30 min
(Figure 3D) or 3 h (Figure 3E), tumor cells-platelets complex was quantified in lung sections by
immunofluorescence. We used a dose 20 times lower of PNH on this experiment, because our in vitro
analyses showed that PNH inhibits adhesion of LS180 colon carcinoma cells to P-selectin more efficiently
than HEP. Figure 3 shows that at both time points, the lung capillaries of the animals treated with the
GAGs presented fewer aggregates than those treated with saline. Furthermore, platelets-tumor cell
aggregation was inhibited to the same extent by PNH and HEP, despite the use of a much lower dose
of PNH.
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Figure 3. Heparan sulfate from P. nigra (PNH) hinders in vivo platelet-tumor cell aggregation.
(A–C) Aggregates of MC-38GFP colon carcinoma cells (in green [GFP] and blue [DAPI]) and platelets (in
red [anti-CD41]) formed in the lung microvasculature of mice were analyzed by immunofluorescence.
Quantification of aggregates present in the lungs of animals treated during 30 min (D) or 3 h (E) with
saline (white squares), 1 mg/kg PNH (blue) or 20 mg/kg porcine heparin (gray). Results were expressed
as percentages of aggregated tumor cells (20 fields per lung, three animals per treatment) and compared
by analysis of variance (ANOVA); NS (no statistical significance) and * (p < 0.05).
2.3. PNH Prevents Lung Metastases of Colon Carcinoma Cells in Mice
Because metastasis efficiency depends on the platelet and tumor cell association, we evaluated
the efficacy of PNH in preventing the onset of lung metastasis in mice 28 days after i.v. injection of
GFP-positive MC-38 cells (Figure 4A). Both macroscopic counting of metastatic foci (Figure 4B) and
fluorescence quantification present in lung homogenates (Figure 4C) showed that a single dose of
PNH (1 mg/kg), administered intravenously 15 min before the injection of MC-38 cells, dramatically
reduces (p < 0.05) the incidence of lung metastases relative to control (up to 100 foci per lung observed
in animals treated with saline) (Figure 4A–C). Considering that it has no cytotoxic effect on MC-38 cells
(Figure 2), the high anti-metastatic activity may be directly related to the ability of PNH to prevent
P-selectin mediated formation of CTMs, decreasing their survival in the bloodstream and preventing
metastatic colonization.
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Figure 4. P. nigra heparan sulfate (PNH) prevents lung metastasis of colon carcinoma in mice.
Representative images (A), metastatic foci (B) and fluorescence quantification (C) of lung metastases
present in mice treated with a single dose of PNH (1 mg/kg; blue circles) or saline (white squares)
15 min before injection of MC-38GFP colon carcinoma cells. Results (seven animals per group) were
compared by t-test; * (p < 0.05) and ** (p < 0.001).
2.4. PNH Has Low Anticoagulant and Antithrombotic Activities and Hypotension Potential
The major challenge of using HEPs as antitumoral or anti-metastatic agents is the large risk for
bleeding and hemorrhage due to their strong anticoagulant activity. For this reason, we evaluated
the potential of PNH to cause hemorrhage by assessing its anticoagulant and antithrombotic activity.
Our previous study showed that PNH slightly increased the clotting time, as shown in (Figure 1C) [21],
and its anticoagulant activity was determined as 2.46 IU/mg, around 60-fold lower than that of UFH
(~180 IU/mg). Therefore, we evaluated the ability of PNH to potentiate antithrombin (AT) or heparin
cofactor II (HCII)-mediated factor IIa or factor Xa inhibition. The EC50 of PNH for AT-mediated
FIIa and FXa inhibition was 9.98 and 17.32 µg/mL, respectively, far higher than UFH (EC50 = 0.10
and 0.22 µg/mL) (Figure 5A,B). Likewise, the EC50 of PNH for HCII-mediated FIIa inhibition was
3.18 µg/mL, four-fold higher than that of UFH (EC50 = 0.79 µg/mL) (Figure 5C).
Next, we determined whether PNH has antithrombotic activity in vivo. We employed a mouse
model of ferric chloride-induced arterial thrombosis, and evaluated carotid artery occlusion time after
injury [20]. Animals treated intravenously with 1 or 2 mg/kg of PNH showed similar occlusion time
when compared to those receiving saline (control) (Figure 5D). Nevertheless, a higher dose of PNH
(4 mg/kg) was able to double the occlusion time compared to the control, but it was significantly less
effective (p < 0.05) than UFH administered at 40-fold lower doses (0.1 mg/kg) (Figure 5D). These results
indicate that the metastasis-preventing dose of PNH (1 mg/kg) has a minimal antithrombotic effect
in mice.
Previous reports have shown that the fucosylated chondroitin sulfate (FucCS), a GAG composed of
a CS core decorated with branches of sulfated fucose, purified from the body-wall of the sea cucumber
Holothuria grisea may provoke kallikrein-mediated hypotension by activating FXII (FXIIa) [15]. Hence,
we used a chromogenic assay to evaluate the potential of PNH to cause FXIIa-triggered hypotension by
comparing its ability to promote the generation of kallikrein relative to the H. grisea FucCS. Our in vitro
chromogenic assays demonstrate that PNH is approximately six-fold less potent (p < 0.05) than H. grisea
FucCS in activating prekallikrein (Figure 5E).





Figure 5. Anticoagulant, antithrombotic and pro-FXIIa activities of the heparan sulfate from P. nigra
(PNH). Doses (EC50) of PNH and UFH promoting in vitro AT-mediated anti-FIIa and anti-FXa (A,B)
and HCII-mediated anti-FIIa (C) activities. Results expressed as IU/mg and EC50 in panels A–C (means,
three independent assays) were compared by t-test. Gray triangles—UFH and blue circles—PNH.
(D) Effects of saline (white squares), UFH (0.1 mg/kg) and crescent doses of PNH (1→4 mg/kg) on the
thrombus formation in arteries of mice. Occlusion times (seven animals per condition) were compared
by analysis of variance (ANOVA). (E) FXII activation promoted by PNH (blue circles) and H. grisea
FucCS (red diamonds) was estimated by assessing in vitro activation of prekallicrein present in human
plasma with basis on the increase in absorbance (405 nm) promoted by the chromogenic substrate for
kallikrein; results expressed as optical density/min (mean, three independent assays) were compared
by t-test. NS (no statistical significance) and * (p < 0.05).
3. Discussion
Although metastasis is the main cause of mortality for most malignant tumors, therapeutic agents
targeting its prevention are not clinically available yet. Current treatment of metastatic tumors is mostly
based on surgical excision and/or chemotherapy, which often present poor outcomes in prolonging
patient survival [24,25]. Nevertheless, the search for new therapeutic compounds aiming different
events of the metastatic cascade has shown promising results [25]. PNH from the ascidian P. nigra
demonstrated, in this work, a significant anti-metastatic activity associated with low bleeding and
hypotensive potential, suggesting that it is a strong candidate for development of a novel therapeutic
agent for metastatic tumor treatment.
HSs from different sources should be studied as a family of related polysaccharides rather
than a single GAG type considering their significant compositional variability [26]. Despite the
intrinsic heterogeneity, the distinct disaccharide components of mammalian HSs are often arranged
as repetitive building-blocks along their chains [26]. Previous two-dimensional (2D) NMR spectra
assessments performed by our group have already demonstrated that PNH possesses increased
proportions of disaccharides containing N-acetyl α-glucosamine and/or β-glucuronic acid (>50%),
which is characteristic of HSs, but they are randomly arranged along their chains [21].
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The primary GAG mechanism for metastasis prevention relies on disrupting the
P-selectin-mediated interaction between CTCs and platelets, compromising the formation of CTMs,
which are responsible for improving tumor cell survival during hematogenous dissemination [27].
DSs from S. plicata and P. nigra, which are mostly composed of disulfated disaccharides containing
2-sulfated α-iduronic acid linked to 4-sulfated or 6-sulfated N-acetyl α-galactosamine, can inhibit
P-selectin at similar doses (IC50 = 13 µg/mL), whereas porcine DS, enriched in monosulfated
disaccharides of α-iduronic acid→N-acetyl α-galactosamine 4-sulfated (up to 95%), is ineffective [8].
Likewise, HS purified from the viscera of the scallop N. nodosus, which presents increased proportions
of monosulfated β-glucuronic acid→N-acetyl α-glucosamine disaccharides (>70%), also inhibits
P-selectin (IC50 ~ 30 µg/mL) [28]. Both PNH and other GAGs with low sulfate content have already
shown higher efficacy to inhibit P-selectin compared to the highly anionic UFH [22,29]. For this reason,
the capacity of distinct GAGs to bind to P-selectin seem to be related to the presence of oligosaccharide
sequences bearing specific conformational features (e.g., ring shapes, torsion angles and spatial
distribution of sulfate groups) along their chains rather than relying exclusively on anionic strength [30].
Furthermore, in the present study, we demonstrated that PNH has also higher efficacy in preventing
the formation of CTMs than UFH (20-fold), DSs from S. plicata and P. nigra (four-fold) and N. nodosus HS
(eight-fold), indicating stronger anti-metastatic potential than other GAGs obtained from vertebrates
or invertebrates [22,28,29].
As observed for PNH during our in vivo experiments, DSs from S. plicata and P. nigra, as well as
FucCS from the sea cucumber H. grisea, also attenuate (>95%) lung metastases of MC-38 colon
carcinoma cells in mice [8,31]. Similarly, N. nodosus HS is effective in decreasing (>75%) the incidence
of lung metastases of LLC lung carcinoma cells injected intravenously in mice [28]. Despite being less
effective, UFH and LMWHs also exert satisfactory P-selectin-mediated anti-metastatic activities [22,23].
Furthermore, a few clinical trials indicate that administration of UFH and LMWHs dalteparin,
nadroparin and certoparin might bring benefit clinical outcomes to patients with different solid tumors
in advanced stages [32]. Although we did not evaluate whether PNH can modulate other pathways in
cancer, where GAG treatment has shown positive outcomes, such as E-cadherin up-regulation and
HGF, heparanase and galectin-3 inhibition, its structural resemblance with other HSs/HEPs allows us
to speculate that PNH could exert pharmacological effects in different events of the metastatic cascade
and might act as anti-metastatic agent in a synergistic manner [22,33–36].
The anticoagulant activity of UFH is due to the AT/HCII-mediated inactivation of several
coagulation system enzymes, especially FIIa, and FXa [37]. Our in vitro assays revealed that PNH exerts
a negligible anticoagulant activity, mostly mediated by HCII. This reduced AT-mediated anticoagulant
potency may occur due to the absence of the specific pentasaccharide sequence present in UFH,
which promotes the conformational change responsible for potentiating AT [37,38]. Despite presenting
mostly a serpin-independent anticoagulant activity, the FucCS from H. grisea also activates HCII;
nevertheless, its activity (~50 IU/mg) is far higher than that obtained with PNH [15]. N. nodosus
HS is also more anticoagulant (38 IU/mg) than PNH [28]. On the other hand, DSs from S. plicata
and P. nigra have anticoagulant activities (~8.0 and ~0.5 IU/mg, respectively) similar to PNH [8].
Some low-molecular-weight HEP derivatives with very-low-anticoagulant activities (up to 1 IU/mg
anti-Xa activity) were also able to attenuate metastasis in mice, but at higher doses (up to 20-fold) than
PNH [39].
Pharmaceutical doses of UFH and LMWHs required to effectively inhibit either P-selectin
or other therapeutic targets of the metastatic cascade may provoke bleeding on patients [22,23].
Previous attempts to develop HEP derivatives, as well as semi-synthetic GAG-like oligosaccharides
(SAGEs), which are depleted of anticoagulant activity but effective in preventing metastasis, have shown
poor pharmaceutical outcomes [22,23,40]. Therefore, the low-anticoagulant GAGs with high
anti-metastatic activities found in marine invertebrates, especially PNH and DSs from ascidians,
are attractive sources of novel drugs to prevent metastasis. Moreover, the low but detectable
antithrombotic effect of PNH might also attenuate the procoagulant state commonly observed in cancer
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patients without increasing the bleeding risk [32]. In addition, the low ability to activate kallikrein,
involved in hypotension events, is an advantage of PNH compared to other GAGs [15].
Notwithstanding the pharmacological potential, the production of GAG-based drugs such as
PNH on an industrial scale relies on a constant supply of large amounts of animal raw material.
The ascidian Ciona intestinalis, which has been mass-produced via aquaculture as a source of biomass
to produce biogas by Swedish and Norwegian companies, presents in their viscera anti-metastatic DS
similar to that found in P. nigra [41]. Moreover, scallops of the genus Nodipecten containing HS effective
in preventing metastasis are largely cultivated for food purposes in marine farms spread around
the world [28,42]. Considering that the viscera of both C. intestinalis and N. nodosus are underused
or discarded, their use would not affect the target products of the aquaculture industry, and thus,
the current farming should be fully capable of supplying marine raw material for manufacturing novel
GAG-based anti-metastatic drugs.
4. Material and Methods
4.1. Samples and Cell Lines
DS and HEP/UFH from porcine mucosa and 4-sulfated (CS-4S) and 6-sulfated (CS-6S) CSs
from porcine or shark cartilage, employed as GAG’s standards, were purchased from Sigma-Aldrich
(St. Louis, MO, USA). The 6th international Heparin Standard (2154 UIs per vial, Lot No. 07/328) was
obtained from the National Institute for Biological Standards and Control (Potters Bar, UK). The FucCS
from Holothuria grisea was kindly provided by Dr. Gustavo Santos (Federal University of Rio de Janeiro,
Rio de Janeiro, Brazil). Human colon carcinoma cells (LS180) purchased from ATCC (Manassas, VA,
USA) were grown in minimum essential medium-α (Invitrogen; Carlsbad, CA, USA) supplemented
with 10% FBS (Invitrogen). Mouse colon carcinoma cells (MC-38) expressing green fluorescent protein
(MC-38GFP) [8], provided by Dr. Lubor Borsig, were grown in Dulbecco’s modified Eagle’s medium
with 4.5 g/L glucose (Sigma-Aldrich) supplemented with 10% FBS (Invitrogen). All reagents were
purchased from Sigma-Aldrich unless otherwise stated.
4.2. Isolation and Purification of PNH
Adult specimens of the ascidian P. nigra were collected in the Ilha Grande Bay (Rio de Janeiro state,
Brazil) by scuba diving. Sulfated polysaccharides from the viscera of P. nigra were extracted through
proteolytic digestion with papain, and then, PNH was purified with anion-exchange chromatography,
as previously described [21,43]. Briefly, crude polysaccharide extracts from P. nigra were applied
into a DEAE-cellulose column, equilibrated with 50 mM sodium acetate (pH 5.0), and then eluted
through a linear gradient of 0.5→1.0 M NaCl. Fractions of 4 mL were collected and checked for
metachromasy [43]; four peaks were identified at different NaCl concentrations. Fractions containing
each peak were pooled together, dialyzed against distilled water, lyophilized and stored at −20 ◦C for
further utilization. PNH disaccharide composition was previously shown by NMR analysis [21].
4.3. Cell Viability Assay
To evaluate cytotoxicity of PNH, an MTT reduction assay was performed. 2 × 104 MC-38 cells
were seeded to a 96-well plate (Jet Biofil, Guangzhou, China) and cultured with 0.1; 1.0 or 10.0 µg/mL
of PNH for 24 h (200 µL of final volume). Then, 500 µg of MTT was added to the wells and incubated
for 2 h at 37 ◦C in an atmosphere of 5% CO2. After this period, MTT was solubilized with DMSO and
the absorbance was read in a microplate reader (560 nm). Cells cultured without PNH were identified
as the control group and its absorbance was considered 100% of viability. This experiment was done
in triplicate.
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4.4. In Vivo Platelet-Tumor Cell Aggregation
Assessments of in vivo formation of tumor cell-platelet aggregates were performed as previously
described [8]. C57BL/6 mice of 8–12 weeks old (~25 g; both sexes) were anesthetized via intramuscular
injection of 10 mg/kg ketamine (Cristalia; São Paulo, Brazil) and 1.6 mg/kg xylazine (Bayer; São Paulo,
Brazil). Subsequently, PNH (1 mg/kg), UFH (20 mg/kg) or saline (control) were intravenously
administered in their tail vein, followed by a tail vein injection of 3× 105 MC-38GFP cells 10 minutes later.
Lungs from animals euthanized 30 min or 3 h after treatment were analyzed by immunofluorescence
using an Axio Imager A1 microscope (Zeiss; Oberkochen, Germany). Frozen sections of the lungs were
incubated with rat anti-mouse CD41 antibody (BD Life Sciences; Franklin Lakes, NJ, USA) and then
by goat anti-rat Alexa 568-conjugated antibody for labeling the platelets. Twenty fields/lung section
in four sections per lung were analyzed. The number of aggregates present in animals treated with
PNH, UFH, and saline was compared by ANOVA followed by Bonferroni post-test using Origin 8.0
software. All the in vivo assays were performed by following, in a strict manner, the guidelines of our
institution (Federal University of Rio de Janeiro) for animal care and experimentation approved by the
local ethical committee (approval number 01200.001568/2013-87, protocol 054/19).
4.5. Experimental Metastasis Model
The anti-metastatic effect was evaluated by quantifying lung metastases in C57BL/6 mice treated
intravenously with a single dose of PNH (1 mg/kg) or saline (control) 15 min before injection of
3 × 105 MC-38GFP cells. After 28 days, animals were euthanized and macroscopical metastatic foci
present in their lungs were counted. Measurements of fluorescence emitted by MC-38GFP cells present
in lung homogenates were performed as described elsewhere [8]. The anti-metastatic efficacy of
PNH compared to the control group was analyzed by t-test using Origin 8.0 software (OriginLab;
Northampton, MA, USA).
4.6. In Vitro Anti-FIIa and -FXa Activities
PNH and UFH were subjected to FIIa and FXa amidolytic activity assessments by measuring the
hydrolysis of chromogenic substrates [32]. AT (50 nM) or HCII (68 nM) from Hematologic Technologies
(Essex Junction, Chittenden, VT, USA) were incubated in TS/PEG buffer (0.02 M Tris/HCl, 0.15 M NaCl
and 1.0 mg/mL polyethylene glycol 8000, pH 7.4) and then 2 nM FIIa or FXa (Hematologic Technologies)
was added to trigger the reaction. After incubation (60 s at 37 ◦C), residual FIIa or FXa activities were
determined by adding 100 µM of chromogenic substrates S-2238 or S-2765, respectively (Chromogenix;
Molndal, Sweden), and then recording absorbance (405 nm) during 300 s in a ThermoMax Microplate
Reader (American Devices; Sunnyvale, CA, USA). Anti-FIIa and -FXa potencies of PNH and UFH
(IC50) were compared by t-test using Origin 8.0 software (OriginLab).
4.7. In Vivo Antithrombotic Activity
The effectiveness of PNH in preventing arterial thrombosis was evaluated with an in vivo
model [20]. Carotid arteries of C57Bl/6 mice isolated by surgical dissection were placed under an
ultrasonic probe (Transonic System; Ithaca, NY, USA) for monitoring blood flow and then PNH
(1→4 mg/kg), UFH (0.1 mg/kg) and saline (control) were administered intravenously to the animals.
Thrombus was induced by laying a filter piece soaked with 10% ferric chloride over the isolated artery
for 3 min and then monitored for 60 min or up to the complete occlusion of the artery (occlusion time).
Antithrombotic activities of PNH and UFH were compared by ANOVA using Origin 8.0 software
(OriginLab).
4.8. FXII Activation Assay
Different concentrations of PNH or FucCS from H. grisea were incubated with 40 µL human plasma
diluted in TS/PEG (three times). After incubation (60 s at 37 ◦C), activation of FXII was indirectly
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assessed by measuring the conversion of plasma prekallikrein with 0.3 mM kallikrein chromogenic
substrate S-2302 (Chromogenix) and then recording the absorbance (405 nm) for 300 s. The efficacy of
the GAGs in activating FXII was calculated based on the rate of p-nitroanilide formation [15].
5. Conclusions
Compounds such as the S-nitrocaptropil and some PEGylateted-thioaptamers (ESTAs) were
shown to impair metastasis by inhibiting P- or E-selectin in preclinical evaluations [44,45]; nevertheless,
none of them has shown satisfactory progress in clinical trials thus far. The comprehensive set of
in vitro and in vivo assays presented here shows that PNH purified from the viscera of the ascidian
P. nigra has high anti-metastatic activity and low bleeding and hypotensive potential; therefore, it could
be an interesting candidate to be tested in future clinical trials.
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